RCKT is trading at $3.52 (8.3% up) in pre-market, rebounding from recent weakness following FDA-related volatility and a wider Q1 loss reported earlier this quarter.
- The upward move aligns with broader indices trading higher, suggesting the gain reflects improved market risk sentiment rather than fresh company-specific developments overnight.
- Investors appear to be buying the dip after the stock faced significant pressure from recent regulatory uncertainty and its latest financial results.